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Abstract
Following a request from the European Commission, the EFSA Panel on Dietetic Products, Nutrition and
Allergies (NDA) was asked to deliver an opinion on the fermented soybean extract NSK-SD® as a novel
food (NF) submitted pursuant to Regulation (EC) No 258/97 of the European Parliament and of the
Council, taking into account the comments and objections of a scientiﬁc nature raised by Member States.
The NF is the fermented soybean extract NSK-SD®, which is standardised to a nattokinase enzyme
activity of 20,000–28,000 ﬁbrin degradation units/g. The information provided on the composition of the
NF, the speciﬁcations, batch-to-batch variability and the stability is sufﬁcient and does not raise safety
concerns. The proposed maximum intake is 100 mg NSK-SD®/day as a food supplement. The target
population proposed by the applicant is healthy men and women over the age of 35 years, excluding
pregnant and lactating women. The Panel noted that nattokinase exhibits in vitro ﬁbrinolytic activity and
in vivo thrombolytic activity in animals when administered parenterally. However, the information
provided with respect to absorption, distribution, metabolism and excretion of the NF does not allow
conclusions to be drawn on the absorption of active nattokinase or any functional metabolites therefrom.
A bacterial reverse mutation test did not show any indication of mutagenicity, and the NF was not
clastogenic in an in vitro chromosome aberration assay. Taking into account the no observed adverse
effect level (NOAEL) of 1,000 mg/kg body weight per day in the subchronic toxicity study in rats, and
considering the proposed maximum intake level for the NF, the Panel concludes that the margin of
exposure is sufﬁcient. The Panel concludes that the NF, the fermented soybean extract NSK-SD®, is safe
under the intended conditions of use as speciﬁed by the applicant.
© 2016 European Food Safety Authority. EFSA Journal published by John Wiley and Sons Ltd on behalf
of European Food Safety Authority.
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Summary
Following a request from the European Commission, the EFSA Panel on Dietetic Products, Nutrition
and Allergies (NDA) was asked to deliver an opinion on the fermented soybean extract NSK-SD® as a
novel food (NF) submitted pursuant to Regulation (EC) No 258/971 of the European Parliament and of
the Council, taking into account the comments and objections of a scientiﬁc nature raised by Member
States. The assessment follows the methodology set in Commission Recommendation 97/618/EC of 29
July 19972 concerning the scientiﬁc aspects and the presentation of information necessary to support
applications for the placing on the market of novel foods and novel food ingredients and the
preparation of initial assessment reports under Regulation (EC) No 258/97 of the European Parliament
and of the Council. The assessment is based on the data supplied in the original application, the initial
assessment by the competent authority of Belgium, the concerns and objections of the other Member
States and the responses of the applicant.
The NF is the fermented soybean extract NSK-SD®. The extract contains nattokinase, which is a
serine protease composed of 275 amino acid residues. Nattokinase was originally isolated from natto,
a traditional Japanese foodstuff which is produced by the fermentation of soybeans (Glycine max L.)
with Bacillus subtilis var. natto. The soybean extract NSK-SD® is standardised to a nattokinase enzyme
activity of 20,000–28,000 ﬁbrin degradation units (FU)/g. The information provided on the composition
of the NF, the speciﬁcations, batch-to-batch variability and the stability is sufﬁcient and does not raise
safety concerns.
The production process is sufﬁciently described and does not raise concerns about the safety of the
NF.
The applicant intends to use the fermented soybean extract NSK-SD® in food supplements. The
target population proposed by the applicant is healthy men and women over the age of 35 years,
excluding pregnant and lactating women. The proposed maximum intake is 100 mg NSK-SD®/day
(corresponding to a maximum of 2,800 FU/day).
Taking into account the composition of the NF and the intended use levels, the Panel considers that
the consumption of the NF is not nutritionally disadvantageous.
The Panel notes that nattokinase exhibits in vitro ﬁbrinolytic activity and in vivo thrombolytic activity
in animals when administered parenterally. However, the information provided with respect to
absorption, distribution, metabolism and excretion of the NF does not allow conclusions to be drawn
on the absorption of active nattokinase or any functional metabolites therefrom.
A bacterial reverse mutation test did not show any indication of mutagenicity. The NF was not
clastogenic in an in vitro chromosome aberration assay.
In a subchronic 90-day oral toxicity study, NSK-SD® (enzyme activity 21,900 FU/g) was
administered to Sprague–Dawley rats at doses of 0, 100, 300 or 1,000 mg/kg body weight (bw) per
day. Based on the observations from this study (including the absence of statistically signiﬁcant
ﬁndings in haematological parameters), the Panel considers that the no observed adverse effect level
(NOAEL) is 1,000 mg/kg bw per day, the highest dose tested.
A number of unpublished and published human studies were provided, which were carried out
in both healthy and diseased subjects including people on anticoagulants. Owing to the low power
of the studies and inconsistencies in results between and within the studies, the Panel considers
that the evidence provided in the human studies is insufﬁcient to conclude on the safety of the
NF.
Information was provided on the microbiological status of the NF. The Panel considers that the
information provided does not raise safety concerns.
With regard to allergenicity, the Panel considers that the risk of allergic reactions to the NF is not
dissimilar to that associated with other soy-derived products.
1 Regulation (EC) No 258/97 of the European Parliament and of the Council of 27 January 1997 concerning novel foods and
novel food ingredients (OJ L 43, 14.2.1997, p. 1). http://eur-lex.europa.eu/LexUriServ/LexUriServ.do?uri=CONSLEG:
1997R0258:20090120:EN:PDF
2 97/618/EC: Commission Recommendation of 29 July 1997 concerning the scientiﬁc aspects and the presentation of information
necessary to support applications for the placing on the market of novel foods and novel food ingredients and the preparation
of initial assessment reports under Regulation (EC) No 258/97 of the European Parliament and of the Council (OJ L 253,
16.9.1997, p. 1–36). http://eur-lex.europa.eu/legal-content/EN/TXT/?uri=uriserv:OJ.L_.1997.253.01.0001.01.ENG
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Taking into account the NOAEL of 1,000 mg/kg bw per day in the subchronic toxicity study in rats,
and considering the proposed maximum intake level for the NF of 100 mg NSK-SD®/day
(corresponding to 1.43 mg/kg bw per day for a 70-kg person), the Panel concludes that the margin of
exposure (of 700) is sufﬁcient.
The Panel concludes that the NF, the fermented soybean extract NSK-SD®, is safe under the
intended conditions of use as speciﬁed by the applicant.
Safety of fermented soybean extract NSK-SD®
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1. Introduction
1.1. Background and Terms of Reference as provided by the European
Commission
On 8 May 2014, the company Japan Bio Science Laboratory (JBSL) submitted a request under
Article 4 of the Novel Food Regulation (EC) No 258/973 to place on the market a fermented soybean
extract (Nattokinase NSK-SD®) as a novel food (NF).
On 1 December 2014, the competent authority of Belgium forwarded to the Commission its initial
assessment report, which came to the conclusion that the fermented soybean extract (Nattokinase
NSK-SD®) meets the criteria for acceptance of a NF deﬁned in Article 3(1) of Regulation (EC) No 258/79.
On 6 January 2015, the Commission forwarded the initial assessment report to the other Member
States (MS). Several of the MS submitted comments or raised objections.
The concerns of a scientiﬁc nature raised by the MS can be summarised as follows:
• Some MS commented that no data have been provided on the long-term safety of the NF. MS
expressed concerns that the product might have effects on haematological parameters, in
particular on blood coagulation. One case report (Chang et al., 2008) was identiﬁed, in which a
patient on antihypertensive agents and low-dose aspirin for secondary stroke prevention
experienced an acute cerebellar haemorrhage and cerebral microbleeds after concomitant
consumption of nattokinase.
• Some MS requested further details on the composition of NSK-SD®, in particular with regard to
the starch carrier and the protein fraction in NSK-SD® and their potential to elicit allergic
reactions.
• Some MS commented that no evidence was provided to substantiate whether the nattokinase
consumed orally was absorbed into the blood stream.
• One MS expressed concerns with regard to potential adverse effects of the nattokinase on
mucous membranes.
In accordance with Article 29(1)(a) of Regulation (EC) No 178/20024, the European Food Safety
Authority (EFSA) is asked to carry out the additional assessment for the fermented soybean extract
NSK-SD® as a NF in the context of Regulation (EC) No 258/97.
EFSA is asked to carry out the additional assessment and to consider the elements of a scientiﬁc
nature in the comments raised by the other MS.
2. Data and methodologies
2.1. Data
The assessment of the safety of this NF is based on data supplied in the original application, the
initial assessment by the competent authority of Belgium, the concerns and objections of the other MS
and the responses of the applicant (See ‘Documentation provided to EFSA’).
In accordance with Commission Recommendation 97/618/EC,5 the fermented soybean extract
NSK-SD® is allocated to Class 2.1, i.e. the source of the NF has a history of food use in the
Community. The data are required to comply with the information required for NFs of Class 2.1, i.e.
structured schemes I, II, III, IX, X, XI, XII and XIII of Commission Recommendation 97/618/EC. In
the current opinion, these structured schemes are listed in Sections 3.1–3.8. The intention is to use
the NF in food supplement products (in capsule, tablet and powder form). This assessment concerns
only risks that might be associated with consumption of the NF at the proposed conditions of use, and
is not an assessment of the efﬁcacy of the fermented soybean extract NSK-SD® with regard to any
claimed beneﬁt.
3 Regulation (EC) No 258/97 of the European Parliament and of the Council of 27 January 1997 concerning novel foods and
novel food ingredients. OJ L 43, 14.2.1997, p. 1–6.
4 Regulation (EC) No 178/2002 of the European Parliament and of the Council of 28 January 2002 laying down the general
principles and requirements of food law, establishing the European Food Safety Authority and laying down procedures in
matters of food safety. OJ L 31, 1.2.2002, p. 1–24.
5 Commission Recommendation 97/618/EC: Commission Recommendation of 29 July 1997 concerning the scientiﬁc aspects and
the presentation of information necessary to support applications for the placing on the market of novel foods and novel food
ingredients and the preparation of initial assessment reports under Regulation (EC) No 258/97 of the European Parliament and
of the Council. OJ L 253, 16.9.1997, p. 1–36.
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2.2. Methodologies
The assessment follows the methodology set out in Commission Recommendation 97/618/EC of
29 July 1997 concerning the scientiﬁc aspects and the presentation of information necessary to support
applications for the placing on the market of novel foods and novel food ingredients and the preparation of
initial assessment reports under Regulation (EC) No 258/97 of the European Parliament and of the Council.
3. Assessment
3.1. Speciﬁcation of the NF
The NF is a fermented soybean extract with the trade name of NSK-SD®. It contains a proprietary
nattokinase isolated from natto, a foodstuff produced by the fermentation of (non-genetically modiﬁed)
soybeans (Glycine max L.) with a selected strain of Bacillus subtilis var. natto. The fermented soybean
extract NSK-SD® is standardised to have a nattokinase enzyme activity of 20,000–28,000 ﬁbrin
degradation units (FU)/g as assessed by an assay described by Takaoka et al. (2010). One unit (1 FU) is
deﬁned as the amount of enzyme that increases the absorbance (by ﬁbrinogen degradation products) of
the sample at 275 nm by 0.01/min under the conditions as speciﬁed in a spectrophotometry assay
(Takaoka et al., 2010).
The nattokinase is a 27.728 kDa serine proteinase classiﬁed as a member of the subtilisin family
and scientiﬁcally identiﬁed as Subtilisin NAT.NK. It is composed of 275 amino acid residues (Fujita
et al., 1993). The amino acid sequence has been provided by the applicant. The nucleotide sequence
of the nattokinase (Subtilisin NAT) gene exhibits a high homology with other subtilisin enzymes and is
99.5% homologous to subtilisin E and 99.3% homologous to subtilisin amylosaccharitus (Nakamura
et al., 1992). The applicant establishes the identity of the nattokinase in NSK-SD® by DNA sequencing
of NSK-SD®-producing bacteria and comparing the sequence to published data (Nakamura et al.,
1992). The maximum ﬁbrinolytic activity occurs around 65°C at a pH of 10.5.
NSK-SD® is an odourless milk-white coloured powder. It is comprised of 30% fermented soybean
extract powder and 70% resistant dextrin (as carrier) from corn starch, which is added during the
processing. Vitamin K2 is removed during the manufacturing process.
Table 1: Speciﬁcations of NSK-SD®
Parameter Speciﬁcation Method
Nattokinase activity 20,000–28,000 FU/g Assay method of nattokinase(a)
Identity Conﬁrmable IBox method(b), HPLC
Condition No offensive taste or smell Sensory test
Loss on drying ≤ 10% 1 g, 105°C, 4 h
Vitamin K2 ≤ 0.1 ppm HPLC method
Contaminants
Heavy metals ≤ 20 ppm ICP/MS method
Lead ≤ 5 ppm ICP/MS method
Arsenic ≤ 3 ppm ICP/MS method
Microbiological speciﬁcations
Total viable aerobic count ≤ 1,000 CFU/g U.S. FDA BAM (Chapter 3)
Yeast and mould ≤ 100 CFU/g U.S. FDA BAM (Chapter 18)
Coliforms ≤ 30 CFU/g ISO 4832:2006
Spore-forming bacteria ≤ 10 CFU/g(c) Soybean–Casein Digest (SCD) Agar method
Escherichia coli Negative/25 g US FDA BAM (Chapter 4a)
Salmonella sp. Negative/25 g AOAC sec. 967.26
Listeria Negative/25 g AOAC 960701
AOAC: Association of analytical communities; BAM: bacteriological analytical manual; CFU: colony forming units; FDA: US Food
and Drug Administration; FU: ﬁbrin degradation unit; HPLC: high-performance liquid chromatography; ICP/MS: inductively
coupled plasma mass spectrometry; ISO: International Association for Standardization.
(a): As described by Takaoka et al. (2010).
(b): Analysis of the degradation pattern of oxidised insulin chain B by nattokinase employing HPLC (JBSL).
(c): Limit of detection.
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Proximate analyses have been provided for ﬁve batches of NSK-SD®. The product consists primarily
of carbohydrates (> 90% (by calculation)), total protein (ca. 5.5% (Kjeldahl), moisture (ca. 3%
(vacuum oven method)), ash (ca. 0.3% (dry ash method)) and fat (0.1% (Soxhlet)). The percentage
of the carbohydrate content was calculated as 100-(moisture + protein + fat + ash).
The applicant indicated that the contribution of the nattokinase to the total protein fraction is about
89–93%, as derived from calculation considering a puriﬁed (< 99%) nattokinase activity of 480 FU/mg.
According to the applicant, the remaining protein fraction (other than nattokinase) comprises peptides
and amino acids-containing fragments that do not induce an immune response to soy-protein or
nattokinase-speciﬁc antibodies. To support this statement, the applicant submitted the results of an
enzyme-linked immunosorbent assay (ELISA) applied to two batches, where the content of soybean
protein was below the limit of detection (i.e. 1 lg/g).
NSK-SD® has been analysed for potential bioactive compounds and none of the following have
been detected (unless otherwise speciﬁed in brackets): adenine, xanthine, guanine, hypoxanthine,
daidzin (0.5 mg/100 g), daidzein, genistin (1.2 mg/100 g), genistein and tyramine (< 0.5 mg/100 g).
Batch-to-batch analyses (Table 2) were provided for ﬁve different batches of NSK-SD® in order to
conﬁrm that the manufacturing process is reproducible and adequate to produce a product that is
within the speciﬁcations as set above.
The Panel considers that the information provided on the composition, the speciﬁcations and the
batch-to-batch variability of the NF is sufﬁcient and does not raise safety concerns.
3.1.1. Stability of the NF
Nattokinase has been shown to be stable under various pH and temperature conditions (Sumi
et al., 1987). NSK-SD® (packaged in aluminium bags) was conﬁrmed to be stable over an 18 month
period under temperature conditions of 40°C based on its nattokinase activity. At room temperature,
NSK-SD® was shown to be stable for 42 months. In a 25% aqueous solution at a pH of 5.5–10 and at
a temperature of 25°C, NSK-SD® was shown to be stable for 24 h, but it was labile below pH 5.0.
The Panel considers that the data provided sufﬁcient information with respect to the stability of the NF.
Table 2: Analyses of ﬁve batches of NSK-SD®
Parameter Speciﬁcation
Batch results
RWVF1
5/9/2012
SQXB1
21/3/2013
STXI1
28/6/2013
SWVG1
6/9/2013
SZVJ1
9/12/2013
Nattokinase
activity
20,000–28,000 FU/g 23,700 25,300 24,600 24,800 24,100
Identity Conﬁrmable Conforms Conforms Conforms Conforms Conforms
Condition No offensive taste or smell Conforms Conforms Conforms Conforms Conforms
Loss on drying ≤ 10% 3.80 3.10 2.80 2.90 3.40
Vitamin K2 ≤ 0.1 ppm nd nd nd nd nd
Contaminants
Heavy metals ≤ 20 ppm 0.117 0.009 0.009 0.009 0.009
Lead ≤ 5 ppm ≤ 0.01 ≤ 0.01 ≤ 0.01 ≤ 0.01 ≤ 0.01
Arsenic ≤ 3 ppm ≤ 0.1 ≤ 0.1 ≤ 0.1 ≤ 0.1 ≤ 0.1
Microbiological speciﬁcations(a)
Total viable
aerobic count
(CFU/g)
≤ 1,000 CFU/g ≤ 300 ≤ 300 ≤ 300 ≤ 300 ≤ 300
Yeast and mould
(CFU/g)
≤ 100 CFU/g ≤ 10 ≤ 10 ≤ 10 ≤ 10 ≤ 10
Coliforms (CFU/g) ≤ 30 CFU/g ≤ 10 ≤ 10 ≤ 10 ≤ 10 ≤ 10
Escherichia coli Negative/25 g Negative Negative Negative Negative Negative
Salmonella sp. Negative/25 g Negative Negative Negative Negative Negative
Listeria Negative/25 g Negative Negative Negative Negative Negative
CFU: colony forming units; FU: ﬁbrin degradation unit; nd: not detected.
(a): For three additional batches, the applicant provided results on the amount of spore-forming bacteria (including
Bacillus subtilis) which were below the limit of detection (i.e. ≤ 10 CFU/g).
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3.2. Effect of the production process applied to the NF
Soybean powder is fermented at 37°C using a strain of B. subtilis var. natto, with the addition of
corn starch, soybean oil, calcium carbonate and water. Thereafter, nattokinase is isolated by
performing several ﬁltration steps. The product is standardised to an enzyme activity of at least
20,000 FU/g and a maximum of 28,000 FU/g using a suitable carrier (i.e. resistant dextrin). Vitamin K2
is removed during the manufacturing process.
The Panel considers that the production process is sufﬁciently described and does not raise
concerns about the safety of the NF.
3.3. History of the organism used as a source of the NF
B. subtilis var. natto is a subspecies of B. subtilis, a Gram-positive, catalase-positive bacterium
commonly found in soils. B. subtilis was granted Qualiﬁed Presumption of Safety (QPS) status with
qualiﬁcation (EFSA, 2007; EFSA BIOHAZ Panel, 2015).
B. subtilis var. natto has a long history of consumption in Japan. It is used in the commercial
production of natto, which is a traditional Japanese food produced by the fermentation of soybeans
(G. max L.).
3.4. Anticipated intake/extent of use of the NF
The applicant intends to use Nattokinase NSK-SD® in food supplements (as soft-gel capsules, hard-
shell capsules, tablets and powder). The target population for the NF is healthy men and women over
the age of 35, excluding pregnant and lactating women.
The proposed maximum intake is 100 mg NSK-SD®/day, which corresponds to a maximum of
2,800 FU/day (see speciﬁcations).
3.5. Information from previous exposure to the NF or its source
Natto, i.e. boiled or steamed soybeans fermented by B. subtilis var. natto, is a traditional food in
Japan. One portion (50 g) of commercially available natto typically has a nattokinase activity of 1,400–
2,000 FU/pack (Takaoka, 2000; Takaoka et al., 2010), with levels ranging from 600 to 3,290 FU/pack
(Takaoka et al., 2010).
Nattokinase NSK-SD® has been produced since 1996. Sales ﬁgures for Japan and the USA have
been provided.
3.6. Nutritional information on the NF
Taking into account the composition of the NF and the intended use levels, the Panel considers that
the consumption of the NF is not nutritionally disadvantageous.
3.7. Microbiological information on the NF
Microbiological speciﬁcations are presented in Table 1 (Section 3.1). The applicant provided
analytical results for ﬁve batches which were compliant with the microbiological speciﬁcations (Table 2,
Section 3.1). For three additional batches, the applicant provided results on the amount of spore-
forming bacteria, including B. subtilis. The amount of such bacteria in the product was shown (using
the SCD Agar method) to be below the limit of detection, i.e. ≤ 10 CFU/g.
The applicant provided a study (Isowa, 2003) in which culture broth containing the B. subtilis
natto strain used for the production of NSK-SD® was administered to ICR-strain SPF mice (5/sex per
group) in a single oral inoculation of 0 (control group) or 7.55 9 108 CFU/body. No mortalities were
reported nor were any remarkable changes observed on vital signs or body weight (bw) for a period
of 14 days. On day 14, animals were sacriﬁced, and autopsy and histopathology were carried out.
There were no differences between the control group and the group which had been inoculated with
B. subtilis natto.
The Panel considers that the microbiological information provided does not raise safety concerns.
Safety of fermented soybean extract NSK-SD®
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3.8. Toxicological information on the NF
The ﬁbrinolytic activity of nattokinase was ﬁrst identiﬁed in vitro using ﬁbrin plates (Sumi et al.,
1987).
In a clot lysis assay, nattokinase was shown to be able to cleave cross-linked ﬁbrin (Fujita et al.,
1995b). Nattokinase was also shown to raise in vitro the activity of tissue-type plasminogen activator
(tPA) (Yatagai et al., 2008). Moreover, nattokinase was reported to cleave and inactivate plasminogen
activator inhibitor-1 (PAI-1) in vitro (Urano et al., 2001). In another in vitro study (Pais et al., 2006), a
signiﬁcant dose-dependent decrease in red blood cell aggregation and low-shear viscosity was found in
blood samples upon incubation with nattokinase.
Several animal studies reported on an effect of nattokinase on thrombolysis in vivo (Sumi et al.,
1990; Fujita et al., 1995c; Kamiya et al., 2010; Xu et al., 2014).
The Panel notes that nattokinase has in vitro ﬁbrinolytic activity and in vivo thrombolytic activity
when administered parenterally.
3.8.1. Absorption, distribution, metabolism and excretion
The applicant tested soft gel capsules ‘Natural Super Kinase II’ (NSK-II) containing NSK-SD®
in vitro under acidic conditions (pH 2.0, mimicking gastric ﬂuid) in order to get information on the
activity of nattokinase when passing through the stomach. The results of this assay were provided to
EFSA.
One publication (Fujita et al., 1995a) studying the fate of nattokinase in the intestine of male
Wistar rats was provided. After a 24-h fasting, the animals (n = 20) were anaesthetised and a loop of
intestine was extracted through an abdominal incision. A 15 cm long segment of the intestine including
parts of the duodenum and jejunum was tightened at both ends and nattokinase (80 mg/kg) was
injected into this part of the intestine. Before and 0.5, 1, 3 and 5 h after injection of the enzyme,
blood samples were collected from the left femoral vein. There was no control group with animals
being submitted to the same intervention (i.e. with placebo instead of enzyme). The ﬁbrinogen in the
plasma was analysed by sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) under
non-reducing conditions and western blotting (using anti-ﬁbrinogen c-chain antibody). According to the
authors, ﬁbrinogen degradation products were detected in all rats, but breakdown patterns differed. In
14 out of the 20 rats, a 270 kDa fragment appeared within 3–5 h without further degradation of the
fragment, while in the remaining six rats the 270 kDa fragment appeared within 0.5 h which was then
to a low degree degraded to a 105 kDa fragment via a 200 kDa fragment. In parallel with this
ﬁbrinogen degradation, the plasma recalciﬁcation time was prolonged in these six rats at 3 and at 5 h
after administration (mean  SEM coagulation time; before: 2.1  0.5 min, 0.5 h: 2.3  0.6 min, 1 h:
2.5  0.6, 3 h: 6.3  2.0, 5 h: <10 min). Nattokinase was detected in blood samples by western
blotting using anti-nattokinase antibody, but no information on the number of samples analysed was
provided. Besides a protein band of 28 kDa in the same position as nattokinase (MW 27.7 kDa), three
further protein bands (i.e. 48, 42 and 37 kDa) were detected. These bands were also recognised by
anti-ﬁbrinogen antibodies. The nature of these bands is unclear as information on the speciﬁcity of the
antibodies is lacking. The Panel therefore considers that no conclusions can be drawn from this study
on the absorption of active nattokinase in rats.
In a pilot study in humans (Ero et al., 2013), 11 healthy participants (six females, ﬁve males, aged
21–65 years) ingested a single dose of 100 mg nattokinase in softgel form (NSK-SD) containing
2,000 FU. Participants were eligible for the study if they were not taking nattokinase and did not
consume large amounts of natto or soy protein in their diets, if they were not using prescription
medication and were free of aspirin, non-steroidal, anti-inﬂammatory drugs, antihistamines, ﬁsh oils
and other agents with antiplatelet or anticoagulant properties. Blood samples were collected at
baseline and 2, 4, 8, 12, 24 and 48 h after consumption of the nattokinase. A pharmacokinetic pattern
was observed between baseline and 48 h post-dose for nattokinase or its metabolites as measured by
an ELISA using a rabbit, polyclonal, anti-nattokinase antibody. Increases from baseline were shown to
be statistically signiﬁcant in the samples at 2, 4, 8, 12 and 24 h post-dose. However, the Panel notes
the limitations of this study such as the absence of a control group and the use of a non-validated
ELISA. The Panel also notes that the study did not assess the biological activity of nattokinase in
blood.
The Panel considers that the available information does not allow conclusions to be drawn on the
absorption of active nattokinase or its metabolites.
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3.8.2. Genotoxicity
A bacterial reverse mutation test using Salmonella Typhimurium strains TA 98, TA 100, TA 1535 and
TA 1537 and the Escherichia coli strain WP2 uvrA was carried out in compliance with the Japanese
Standard for the testing of drugs and GLP (Fuji Biomedix, 2003a). The test substance ‘Nattokinase DS’
(activity 20,000 FU/g) was dissolved in distilled water and tested at doses up to 5,000 lg/plate. There
was no indication of a mutagenic response in any of the strains tested, neither in the presence nor in
the absence of metabolic activation system (S9 mix).
An in vitro chromosome aberration assay using Chinese hamster lung cells (CHL/IU) was conducted
in accordance with the Japanese Standard for the testing of drugs and GLP (Fuji Biomedix, 2003b).
The test substance ‘Nattokinase DS’ (activity 20,000 FU/g) dissolved in culture medium induced
inhibition of cell growth at concentrations of 0.156 mg/mL and above. Based on the results of cell
growth inhibition tests in the main study, mitotic cells were scored at three dose levels as follows: 78,
110 and 156 lg/mL for the short-term (6-h) treatment without S9 mix (cell proliferation rates were
86.4%, 105.6% and 68.4%, respectively), 55, 78 and 110 lg/mL for the short-term treatment with S9
mix (cell proliferation rates were 93.0%, 82.1% and 102.0%, respectively), and 55, 78 and 110 lg/mL
for the 25-h continuous treatment without S9 mix (cell proliferation rates were approximately 105% at
all three dose levels). No dose-related increases in the number of cells with structural or numerical
chromosome aberrations were observed.
Even if a micronucleus assay, as recommended in the EFSA Scientiﬁc Opinion on genotoxicity
testing strategies (EFSA Scientiﬁc Committee, 2011), has not been provided, the Panel considers that
given the nature of the NF no safety concerns are raised.
3.8.3. Acute toxicity studies
In an acute oral toxicity study (BILIS, 1999) carried out in accordance with the Japanese guidelines
for the testing of drugs, nattokinase (Biozyme NSK-FD, activity approximately 10,000 FU/g) suspended
in distilled water was administered to Sprague–Dawley rats (5/sex per group) at a single dose of
2,000 mg/kg bw. Apart from diarrhoea or soft stool observed on the ﬁrst day after dosing, there were
no indications of adverse effects.
In a more recent study (Bozo Research Center Inc., 2006), nattokinase (NSK-SD, activity
24,700 FU/g) administered orally at doses of 1,000 and 2,000 mg/kg bw to Sprague–Dawley rats
(6/sex per group) induced no adverse effects.
3.8.4. Subacute and subchronic toxicity studies
A repeated-dose 28-day oral toxicity study (Fuji Biomedix, 2002), performed according to the
Guideline for Toxicity Studies of Drugs established by the Japanese Ministry of Health and Welfare
(Notiﬁcation No. 24, 1989; 88, 1993, Japanese Ministry of Health and Welfare), was provided.
Sprague–Dawley rats (6/sex per group) were administered by gavage ‘Nattokinase DS’ (Japanese
name: NSK-SD; 20,000 FU/g) at levels of 0 or 167 mg/kg bw per day (equivalent to 0 or 3,340 FU/kg
bw per day). The amount of nattokinase was calculated as being equivalent to 100 times the usual
intake of natto (50 g/60-kg individual; nattokinase activity of fermented soybeans approximately
40 FU/g). Rats were monitored for clinical signs. Body weight and food consumption were recorded,
and urinalysis and ophthalmoscopy were conducted. Blood samples were taken at the end of the
treatment period for haematology and blood chemistry analysis. At necropsy, macroscopic
examinations were carried out and organ weights were determined. Selected organs and tissues were
prepared for histopathological examinations. According to the author, the no observed adverse effect
level (NOAEL) was 167 mg/kg bw per day (the only dose tested).
A subchronic oral toxicity study (Bozo Research Center Inc., 2004) has been conducted on
‘Nattokinase DS’ (Japanese name: NSK-SD) in compliance with the Japanese Standard for the testing
of drugs and GLP. The test material (enzyme activity of the batch used: 21,900 FU/g) was dissolved in
water and administered by gavage to Sprague–Dawley rats (12/sex per group) for 90 days at doses of
0, 100, 300 or 1,000 mg/kg bw per day.
The animals were housed individually and examined for general condition at least twice daily. Body
weights and feed consumption were recorded at least twice weekly. Ophthalmoscopy was conducted
on all animals prior to the start of treatment and on 6/sex per group during week 13. Blood was
collected from all animals prior to necropsy and examined for haematological parameters (red blood
cell count (RBC), haemoglobin (Hb), haematocrit (Ht), mean corpuscular volume (MCV), mean
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corpuscular haemoglobin (MCH), mean corpuscular haemoglobin concentration (MCHC), reticulocyte
percentage, thrombocyte count, white blood cell count (WBC), differential white blood cell count,
prothrombin time (PT), activated partial thromboplastin time (aPTT), ﬁbrinogen). Serum was examined
for clinical biochemistry parameters (alkaline phosphatase (ALP), alanine aminotransferase (ALT),
aspartate aminotransferase (AST), lactate dehydrogenase (LDH), gamma-glutamyltransferase (GGT),
total cholesterol, triglycerides, phospholipids, total bilirubin, glucose, blood urea nitrogen (BUN),
creatinine, Na, K, Cl, Ca, P, total protein (TP), albumin, albumin/globulin (A/G) ratio, protein fractions).
Urine was collected from all animals overnight and examined for a range of endpoints.
A necropsy including macroscopic examination of tissues and weighing of organs (brain, pituitary,
thyroids (including parathyroids), adrenals, thymus, spleen, heart, lungs (including bronchus),
submandibular and sublingual glands, liver, kidneys, testes, prostate, seminal vesicle, ovaries and
uterus) was conducted on all animals. A full range of tissues was preserved for histological
examination and the high-dose and control groups were microscopically analysed.
No deaths occurred during the administration period and there were no treatment-related clinical
signs. Body weight of male animals of the mid-dose group was statistically signiﬁcantly lower
compared with the control group from day 66 to 87 of treatment (max. 8%). Feed consumption in
males of the mid-dose group was signiﬁcantly lower from day 42 to 84 and occasionally also in males
of the high-dose group (days 66, 70, 77 and 84). Female animals showed no statistically signiﬁcant
differences in body weight and feed consumption, and there were no signiﬁcant differences in total
body weight gain of males and females.
Ophthalmoscopy showed no abnormalities. There were no statistically signiﬁcant differences in
haematological parameters (including PT, aPTT, ﬁbrinogen, thrombocyte counts). Clinical biochemistry
analyses showed a signiﬁcantly higher ALP activity in males of the high-dose group and females of the
mid-dose group. Mid-dose females also had signiﬁcantly higher total cholesterol and phospholipid
concentrations and mid-dose males had a lower total bilirubin concentration as well as a lower
percentage of b-globulin in protein fractions. Urinalysis showed statistically signiﬁcantly lower
concentrations of Na, K and Cl, and a higher creatinine concentration in high-dose females. On request
of the NDA Panel, the applicant conﬁrmed that the mean values for the urine parameters (except
creatinine, for which no data were available) fell within the historical control ranges.
Organ weight determinations showed a number of statistically signiﬁcant differences in absolute
and/or relative weights. Most of them were observed in the mid- or low-dose group and, in the
absence of a dose relationship, are not considered treatment related. The only signiﬁcant differences
observed in mid- and high-dose males were lower absolute but not relative pituitary and heart
weights. In both cases, the changes were not dose related. High-dose females showed higher absolute
and relative pituitary weights; on request, the applicant conﬁrmed that the mean values were within
the historical control ranges.
Macroscopic examinations at necropsy did not identify any changes associated with treatment.
Microscopic examination of tissues showed no relevant increase in the incidence of histopathological
ﬁndings in animals of the high-dose group compared with the controls.
The NDA Panel considers that the NOAEL for this study is 1,000 mg/kg bw per day (equivalent to
21,900 FU/kg bw per day), the highest dose tested.
3.8.5. Human studies
A number of MS expressed safety concerns with regard to possible effects on haematological
parameters in humans.
A case report (Chang et al., 2008) was identiﬁed, in which a 52-year old woman in Taiwan who had
used antihypertensive agents and low-dose aspirin (100 mg/day) for secondary stroke prevention
experienced an acute cerebellar haemorrhage and cerebral microbleeds after consumption of 400 mg/day
nattokinase for seven consecutive days. The Panel considers that no conclusions can be inferred from
this report on a causal relationship between the intake of nattokinase and haematological effects.
The applicant provided three human studies commissioned by JBSL including healthy subjects
(Kazuya et al., 2006), subjects with cardiovascular diseases taking warfarin (Ninomiya and Yamada,
2008) and stroke patients on antiplatelet treatment (Shah et al., 2004).
A randomised, double-blind, placebo-controlled study (Kazuya et al., 2006) including 31 healthy
volunteers (aged 20–64 years, BMI > 18 to < 28 kg/m2) aimed to assess the safety of oral
consumption of nattokinase. A total of 22 subjects (12 females) were advised to consume daily three
capsules containing each 36.67 mg NSK-SD® (provided by JBSL and which has been sold in the
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Japanese market as ‘Natural Super Kinase II’ since 2001, corresponding to 2,500 FU/day) for 4 weeks,
while nine subjects (4 females) received a placebo during that time. Subjects were examined before,
at the end and 2 weeks after termination of the intervention period. Measured endpoints were clinical
observations, body weight, blood pressure, pulse rate, haematology, clinical chemistry and urinalysis.
Changes in the results of the intervention and placebo group, respectively, before and after the
intervention were assessed by paired t-test, each with sexes combined and segregated. Clinical
laboratory testing included fasting blood sugar, whole protein, albumin, A/G ratio, total bilirubin,
neutral fat, high-density lipoprotein cholesterol (HDL-C), low-density lipoprotein cholesterol (LDL-C),
urea nitrogen, creatinine, Na, K, Cl, AST, ALT, c-glutamyl transpeptidase (c-GTP), ALP, uric acid (UA),
PT in plasma, prothrombin activity value, PT-International Normalization Ratio (PT-INR), aPTT, remnant
lipoprotein cholesterol (RLP-C), white blood cells, red blood cells, Hb, Ht, MCV, MCH, MCHC and
number of thrombocytes. In females, PT-INR decreased from 1.08 to 1.06 after 4 weeks treatment
and to 1.03 after 2 weeks post-treatment (normal range 0.84–1.14), while PT activity rate was
increased in the female food test group at 2 weeks post-treatment (92.2%) compared with before
treatment (88.6%) (normal range 80–100%). Slight but signiﬁcant changes, which were within the
normal range, were observed within both test and placebo group for a number of parameters tested.
No changes were observed for blood pressure or pulse or urinalysis, which included pH, protein,
glucose, occult blood, bilirubin and urobilinogen. Reported adverse events were comparable in both
the intervention and the placebo group. Upon request by EFSA, the applicant provided between group
analyses (comparing the NSK-SD® group with the placebo group) for the blood coagulation-related
parameters. No signiﬁcant differences were observed between the two groups at any time points for
aPTT, PT, prothrombin activity value or PT-INR. Also upon request by EFSA, the applicant conducted
post-hoc power analyses for the coagulation parameters using three separate approaches. The power
for the coagulation parameters examined ranged from 5% to 50% (Cohen0s effect size approach was
indicated to have the greatest power, while the post-hoc approach had the lowest power). The
Panel considers that this study does not show adverse effects on blood coagulation parameters at a
daily intake of 110 mg NSK-SD® in healthy adults for 4 weeks. However, the Panel notes the very low
statistical power of the study.
A double-blind, placebo-controlled study (Ninomiya and Yamada, 2008) was carried out in adults
with cardiovascular diseases taking warfarin. The study was conducted for a total of 6 months in
30 adults (16 males, 14 females, 59  10 years) of whom 15 took 1,700 FU of NSK-II (2 capsules/day)
at breakfast and 15 took a placebo. In another 30 adults (17 males, 13 females, 59  7.7 years),
15 subjects took 3,400 FU of NSK-II (4 capsules/day, 2 after breakfast, 2 after dinner) and 15 took a
placebo. Several clinical symptoms were recorded as outcomes. These included shortness of breath,
walking, coldness of hands and foot, and skin conditions. Various blood biochemistry analyses and
coagulation–ﬁbrinolysis analyses, such as aPTT, PT, PT-INR, D-dimer, plasmin inhibitor complex (PIC),
total PAI-1, and high-sensitivity C-reactive protein (hs-CRP) were also measured. Statistical analysis
was performed using t-test for (1) comparison of the change rate (%) between the prior to and each
month after the intake and the placebo (and a separate comparison of those over 60 years of age); (2)
low-dose subjects vs placebo, low-dose subjects over 60 vs placebo and high-dose subjects vs placebo.
At some of the six measuring times, signiﬁcant differences were found for aPTT, PT, D-dimer, PT-INR,
t-PAI-1 and CRP, when compared to baseline or to the respective placebo value. However, the
Panel noticed the inconsistency of the ﬁndings. Upon request by EFSA, the applicant conducted
additional analyses on the coagulation parameters (comparing placebo with the low- and high-dose
groups) using mixed-model analysis. There were no statistically signiﬁcant results in any of the
parameters at baseline. With regard to the between group analyses, the results were not statistically
signiﬁcant for any of the coagulation parameters, with the exception of PT activity value at 1, 5 and 6
months in the low-dose group which was elevated 1.25-, 1.31- and 1.44-fold at each time point
relative to the control group, respectively. However, the standard deviation was relatively large.
Additionally, for PIC, there was an overall signiﬁcant decrease for the high-dose NSK group relative to
the control (p = 0.01). Again, the standard deviation was high and no statistical differences were
observed at each individual time point. The applicant also conducted power analyses for both
comparisons, i.e. placebo vs low-dose group and placebo vs high-dose group. Using Cohen0s approach,
the statistical power ranged from 18% to 35% for a medium effect size and from 67% to 96% for a
large effect size. The applicant commented that the study was designed as an efﬁcacy study rather
than a safety study. The Panel notes that although some differences between the study groups were
observed these differences were inconsistent and not dose related. In addition, the Panel notes that
this study was not designed and not sufﬁciently powered to demonstrate adverse effects on blood
Safety of fermented soybean extract NSK-SD®
www.efsa.europa.eu/efsajournal 13 EFSA Journal 2016;14(7):4541
parameters. The Panel considers that this study is insufﬁcient to conclude on the safety of NSK in
patients with cardiovascular diseases concurrently taking warfarin.
In an open-label, uncontrolled multicentre study (Shah et al., 2004) run in three hospitals in
Mumbai, 12 patients with acute, mild to moderate ischaemic stroke (seven males and ﬁve females,
mean age 53.3 years) were given three capsules of 50 mg NSK (corresponding to 2,000 FU) over
7 days, orally at 8 h intervals in addition to low molecular weight heparin and antiplatelet treatment
(low-dose aspirin 325 mg). The primary outcome of the study was the prevention of stroke
progression. Safety was evaluated by subjective and objective symptoms, vital signs, haematologic test
and biological examination. The congealing ﬁbrinogenolysis system was examined on the day of
hospitalisation, second and seventh day after taking NSK as secondary endpoint. Using a Wilcoxon
signed-rank test, signiﬁcant changes were detected in various blood and coagulation parameters under
the treatment. Adverse events, such as increase in blood lipids, AST and ALT, haematemesis, lower
respiratory infection, headache, constipation and blood pressure increase, seizure due to termination
of antiepilepsy drug administration and rib fracture, were reported. No urinalysis was performed. The
Panel notes that this study in 12 ischaemic stroke patients on conventional treatment did not include a
control group. The Panel considers that no conclusion can be drawn from this study in patients with
ischaemic stroke with regard to the safety of NSK.
The applicant provided three additional studies (Sumi et al., 1990; Hsia et al., 2009; Kurosawa
et al., 2015) that addressed ﬁbrinolytic effects following consumption of nattokinase.
A double-blind, placebo-controlled, cross-over study (Kurosawa et al., 2015) was carried out in
12 healthy young men (age 22.3  0.6 years, BMI 21.6  0.5). Following the baseline blood draw,
each subject was randomised to receive either a single dose of 2,000 FU nattokinase (NSK-SD) or
placebo with subsequent cross-over of the groups after a washout of at least 2 weeks. Blood samples
were collected at 2, 4, 6 and 8 h following administration of nattokinase/placebo for analysis of
coagulation–ﬁbrinolysis parameters. For the statistical analysis, two-way repeated measures analysis of
variance between groups was performed. After the intake of nattokinase, signiﬁcant increases were
observed relative to placebo for D-dimer concentrations at 6 and 8 h (1.7 and 2.1-fold, p < 0.05), for
antithrombin at 2 and 4 h (both by 3.6%, p < 0.05), for aPTT at 2 and 4 h (by 3.3% and 3.9%,
p < 0.05) and for ﬁbrin/ﬁbrinogen degradation products (FDP) at 4 h (by 20.8%, p < 0.01), while
factor VIII activity was signiﬁcantly decreased at 4 and 6 h (by 8.9% and 9.8%, p < 0.05). All the
changes, however, were within the normal range. No differences were observed in any of the other
blood parameters analysed (PT-INR, ﬁbrinogen, plasminogen, plasminogen activity, PIC, total PAI-1,
factor VII activity, red and white blood cell counts, thrombocytes, protein, glucose) between
nattokinase and placebo groups at any time point before and after supplementation. Through the
duration of the study, no adverse events were reported by any of the subjects. The Panel notes that in
this study, signiﬁcant changes in coagulation parameters were observed following ingestion of the NF
at the dose tested. However, the Panel notes that the observed changes were within normal ranges.
The Panel considers that from this study that investigated effects of a single dose of the NF in a small
number of healthy young men, no conclusion can be drawn on the overall safety of the long-term
consumption of the NF.
In the open-label, uncontrolled study by Sumi et al. (1990), seven healthy Japanese volunteers
ingested two capsules containing 1.3 g nattokinase (650 mg nattokinase/capsule) three times a day
after meals for 8 days. There was no signiﬁcant difference for the whole blood clot lysis time between
the values before administration of nattokinase and the values on the eighth day. The euglobulin
ﬁbrinolytic activity increased gradually from the ﬁrst to the eighth day (statistically not signiﬁcant). The
level of ﬁbrin/ﬁbrinogen degradation products in serum was signiﬁcantly higher until day 4 following
nattokinase administration (p < 0.001, p < 0.005), as was the amount of tissue plasminogen activator
antigen on days 4 and 8 (p < 0.05). The Panel notes that in this study with high intake of nattokinase
(3.9 g/day) no adverse effects were reported; however, the Panel considers that from this uncontrolled
study in seven healthy Japanese subjects no conclusion can be drawn.
An open-label, uncontrolled clinical trial (Hsia et al., 2009) was conducted in three groups of
15 subjects each: healthy volunteers (‘Healthy Group’), patients undergoing dialysis (‘Dialysis Group’),
and patients with any type of cardiovascular disease (‘Cardiovascular Group’). Patients on
anticoagulant medication (warfarin) were excluded. All subjects ingested two capsules of 400 mg
nattokinase (2,000 FU/capsule) daily for 2 months. An intention-to-treat analysis was performed on all
45 enrolled subjects. By use of mixed-model analysis, a signiﬁcant time effect, but not group effect,
was observed in the change from baseline of ﬁbrinogen (p = 0.003), factor VII (p < 0.001) and
factor VIII (p < 0.001), i.e. plasma levels of the three coagulation factors continuously declined during
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intake. The extent of decrease was similar between groups. After 2 months of administration,
ﬁbrinogen, factor VII, and factor VIII were decreased by 9%, 14% and 17%, respectively, for the
Healthy Group; 10%, 7% and 19%, respectively, for the Dialysis Group; and 7%, 13% and 19%,
respectively, for the Cardiovascular Group. The ﬁbrinogen values for healthy and cardiovascular groups
were within the reference range. While ﬁbrinogen levels in the dialysis group were above the upper
limit of the reference range at baseline, after consumption of nattokinase for 2 months, these levels
had fallen within reference ranges. No notable adverse events were observed in any of the subjects.
The Panel notes that in this uncontrolled study in healthy subjects and in patients, signiﬁcant
decreases in coagulation factors were reported. However, the Panel considers that no conclusions can
be drawn from this uncontrolled study on the safety of the NF.
The Panel considers that in view of the low power of the studies and inconsistencies in results
between and within the studies, the evidence provided by the human studies is insufﬁcient to conclude
on the safety of the NF.
3.9. Allergenicity
The fermented soy bean extract NSK-SD® contains materials from soybeans. NSK-SD® is comprised
of approximately 5% protein. The applicant provided the results of an ELISA used on two batches of
the product, where the content of soybean protein was below the limit of detection (i.e. 1 lg/g NF).
The Panel considers that the risk of allergic reactions to the NF is not dissimilar to that associated
with other soy-derived products.
4. Discussion
The NF is the fermented soybean extract NSK-SD®. The extract contains a speciﬁc serine protease,
nattokinase, and is standardised to an enzyme activity of 20,000–28,000 FU/g. The information
provided on the composition, the speciﬁcations, batch-to-batch variability and the stability of the NF is
sufﬁcient and does not raise safety concerns. The production process is sufﬁciently described and does
not raise concerns about the safety of the NF.
The applicant intends to use the nattokinase NSK-SD® in food supplements. The target population
proposed by the applicant is healthy men and women over the age of 35 years, excluding pregnant
and lactating women. The proposed maximum intake is 100 mg NSK-SD®/day (corresponding to a
maximum of 2,800 FU/day).
Taking into account the composition of the NF and the intended use levels, the Panel considers that
the consumption of the NF is not nutritionally disadvantageous.
The Panel notes that nattokinase exhibits in vitro ﬁbrinolytic activity and in vivo thrombolytic activity
in animals when administered parenterally. However, the information provided with respect to
absorption, distribution, metabolism and excretion of the NF does not allow conclusions to be drawn
on the absorption of active nattokinase or any functional metabolites therefrom.
A bacterial reverse mutation test did not show any indication of mutagenicity. The NF was not
clastogenic in an in vitro chromosome aberration assay.
In a subchronic 90-day repeated dose oral toxicity study, NSK-SD® (enzyme activity of the batch
21,900 FU/g) was administered to Sprague–Dawley rats at doses of 0, 100, 300 or 1,000 mg/kg bw per
day. Based on the observations from this study, the Panel considers that the NOAEL is 1,000 mg/kg bw
per day, the highest dose tested.
A number of published and unpublished human studies were provided, which were carried out in
both healthy and diseased subjects including people on anticoagulants. Owing to the low power of the
studies and inconsistencies in results between and within the studies, the Panel considers that the
evidence provided in the human studies is insufﬁcient to conclude on the safety of the NF.
The Panel notes that in the 90-day rat study no statistically signiﬁcant effects in haematological
parameters (including PT, aPTT, ﬁbrinogen, thrombocyte counts) were observed. Considering the
NOAEL of 1,000 mg/kg bw per day, and the maximum proposed intake level for the NF of 100 mg
NSK-SD®/day (corresponding to 1.43 mg/kg bw per day for a 70-kg person), the Panel concludes that
the margin of exposure (of 700) is sufﬁcient. When considering the enzyme activity of the NF used in
the subchronic toxicity study, the NOAEL amounts to 21,900 FU/kg bw per day. Considering the
maximum proposed intake for the NF of 100 mg/day corresponding to a maximum of 2,800 FU/day
(i.e. 40 FU/kg bw per day for a 70-kg person), the Panel concludes that the margin of exposure (of
550) with regard to the enzyme activity is sufﬁcient.
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5. Conclusions
The Panel concludes that the NF, the fermented soybean extract NSK-SD®, is safe under the
intended conditions of use as speciﬁed by the applicant.
Steps taken by EFSA
1) Letter from the European Commission to the European Food Safety Authority with the
request for a scientiﬁc opinion on the safety of fermented soybean extract (Nattokinase-
NSK-SD®) as a novel food. Ref. Ares(2015)1702324, dated 22 April 2015.
2) Dossier ‘JBSL Nattokinase NF Dossier’ received by EFSA on 7 May 2015, which was
submitted by Japan Bio Science Laboratory (JBSL).
3) On 24 June 2015 and on 18 November 2015, EFSA sent requests to the applicant to provide
missing/complementary information.
4) On 25 and 26 June 2015, on 3 and 7 July 2015 and on 5 February 2016, EFSA received the
missing information as submitted by the applicant.
5) Initial assessment report carried out by the Food Safety Authority of Belgium: ‘OPINION OF
THE SUPERIOR HEALTH COUNCIL No 9205 on the Application for the authorisation of a
“novel food” product “fermented soybean extract (Nattokinase – NSK-SD®)”.’
6) Member States’ comments and objections.
7) Response by the applicant to the initial assessment report and the Member States’
comments and objections.
8) Additional data were provided by the applicant on 7, 8 and 23 September 2015.
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Abbreviations
A albumin
ALT alanine aminotransferase
ALP alkaline phosphatase
aPTT activated partial thromboplastin time
AST aspartate aminotransferase
BMI body mass index
BUN blood urea nitrogen
bw body weight
CFU colony forming units
CHL Chinese hamster lung cells
ELISA enzyme-linked immunosorbent assay
FDA US Food and Drug Administration
FDP ﬁbrin/ﬁbrinogen degradation products
FU ﬁbrin degradation units
G globulin
GGT gamma-glutamyltransferase
GLP good laboratory practice
c-GTP c-glutamyl transpeptidase
Hb haemoglobin
HDL-C high-density lipoprotein cholesterol
HPLC high-performance liquid chromatography
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hs-CRP high-sensitivity C-reactive protein
Ht haematocrit
ICP inductively coupled plasma mass spectrometry
ISO International Association for Standardization
LDH lactate dehydrogenase
LDL-C low-density lipoprotein cholesterol
MCH mean corpuscular haemoglobin
MCHC mean corpuscular haemoglobin concentration
MCV mean corpuscular volume
MS Member State
nd not detected
NDA EFSA Panel on Dietetic Products, Nutrition and Allergies
NF novel food
NOAEL no observed adverse effect level
NSK-II Natural Super Kinase II
PAI-1 plasminogen activator inhibitor-1
PIC plasmin inhibitor complex
PT prothrombin time
PT-INR prothrombin time-International Normalization Ratio
QPS Qualiﬁed Presumption of Safety
RBC red blood cell count
RLP-C remnant lipoprotein cholesterol
SCD soybean–casein digest
SDS-PAGE sodium dodecyl sulfate-polyacrylamide gel electrophoresis
SPF speciﬁc-pathogen free
TP total protein
tPA tissue-type plasminogen activator
UA uric acid
WBC white blood cell count
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